Friday, June 19, 2026
🇺🇸 FDA
DIA pharmaceutical event banner
← Back to Events
Tier 1 Global Networking: High REGULATORY CONCLUDED

DIA — 2026 — Not specified, Philadelphia, USA

Staple biopharma event centered around best practices, regulatory trends, operational excellence, and global compliance frameworks across regulatory, clinical, medical affairs, quality, safety, and digital health.

Not specified, Philadelphia, USA June 14 – June 18, 2026
7,000+ Attendees
3 Presentations
2 Companies
2 Drugs
All Events

Presentation data updated Jun 5, 2026, 11:23 AM UTC

Nova Event Impact Score
47 /100
  • Media coverage 10/20
  • Speaker quality 20/20
  • Pipeline relevance 0/20
  • Historical influence 13/20
  • Company participation 4/20

Key Takeaways

Key Themes

regulatoryDrug Information Association (DIA)Pipeline announcementsPartnership deals

Key Companies

AstraZenecaRoche

Key Drugs

durvalumab + tremelimumabglofitamab

Key Markets

US Americas

Key Opportunities

Partnership dealsLicensing discussionsVendor selection
Best for
Regulatory affairs professionals Investors & analysts

Key Data to Watch

Presentations ranked by investor impact score

ORAL
STARGLO

STARGLO: Phase 3 trial comparing glofitamab plus gemcitabine and oxaliplatin with rituximab plus gemcitabine

Roche glofitamab(Columvi) Phase Iii relapsed/refractory diffuse large B-cell lymphoma NCT04408638
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★★★★ 5/5
POSTER
HIMALAYA

HIMALAYA: Phase III trial of Imfinzi + Imjudo vs Imfinzi in 1L hepatocellular carcinoma

AstraZeneca$AZN durvalumab + tremelimumab(Imfinzi + Imjudo) Phase Iii 1L hepatocellular carcinoma NCT03298451
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★★★★ 5/5
SYMPOSIUM Jun 18

Role of External Data in Confirmatory Clinical Trial: Current Landscape and Future Perspectives